Salesforce shares fell 8.17% amid concerns about the pace of Agentforce revenue, enterprise software spending and acquisition costs ahead of the company's December earnings report.
NYT Connections puzzle No. 1,255 groups words linked to gathering, "Sing a Song of Sixpence", films with exclamation marks ...
The S&P/ASX 200 fell 1.46% as weakening commodity prices, lower oil and a Wall Street technology sell-off pushed all 11 ...
Tuesday's Wordle is a familiar five-letter cooking term with two adjacent vowels, no repeated letters and meanings linked to ...
Summit Therapeutics shares fell nearly 7% to a new 52-week low after the FDA rejected ivonescimab for advanced EGFR-mutated non-small cell lung cancer.
Rigetti shares fell 6.82% to a new 52-week low after disappointing quarterly results, adding to sector-wide losses and investor concerns about revenue, spending and commercial adoption.
IDEAYA Biosciences shares fell 7.61% to $28.05, near a 52-week low, as the company said the FDA could soon review its lead cancer drug darovasertib.
CG Oncology shares fell after RBC downgraded the stock, despite positive Phase 3 results showing its bladder cancer therapy reduced recurrence risk by 68% compared with surveillance alone.
Charles Schwab customers reported difficulty accessing the brokerage's website and accounts shortly after US markets opened, with outage trackers recording more than 1,000 complaints.
The NSA's internal classified communications network reportedly went down, CNN said, citing six sources, while officials investigated the cause and found no evidence of a cyberattack.
Hackers compromised Optimizely, a widely used website platform, to deliver malicious code targeting cryptocurrency, payment card details, browser cookies and iPhones across 178 organisations.
SELLAS Life Sciences said its experimental cancer vaccine significantly improved overall survival in a Phase 3 trial for hard-to-treat acute myeloid leukaemia, sending shares sharply higher.